{
    "organizations": [],
    "uuid": "597c9b9884248229c6c4c78c6cf4654fdbe936b3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aequus-and-camargo-complete-pre-in/brief-aequus-and-camargo-complete-pre-investigational-new-drug-submission-with-fda-for-transdermal-anti-nausea-program-idUSASC09W45",
    "ord_in_thread": 0,
    "title": "BRIEF-Aequus And Camargo Complete Pre-Investigational New Drug Submission With FDA For Transdermal Anti-Nausea Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Aequus Pharmaceuticals Inc:\n* AEQUUS AND CAMARGO COMPLETE PRE-INVESTIGATIONAL NEW DRUG SUBMISSION WITH FDA FOR TRANSDERMAL ANTI-NAUSEA PROGRAM\n* AEQUUS - ANTICIPATES FDA FEEDBACK BY END OF APRIL, WHICH WILL DEFINE CLINICAL STRATEGY FOR REGULATORY APPROVAL IN U.S. FOR AQS1303 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-17T21:13:00.000+03:00",
    "crawled": "2018-04-18T18:33:01.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "aequus",
        "pharmaceutical",
        "inc",
        "aequus",
        "camargo",
        "complete",
        "new",
        "drug",
        "submission",
        "fda",
        "transdermal",
        "program",
        "aequus",
        "anticipates",
        "fda",
        "feedback",
        "end",
        "april",
        "define",
        "clinical",
        "strategy",
        "regulatory",
        "approval",
        "aqs1303",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}